Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Real-time Estimate Cboe BZX
Other stock markets
 12:19:03 2024-04-29 EDT 		5-day change 1st Jan Change
44.8 USD -0.10% Intraday chart for Bristol-Myers Squibb Company -8.69% -12.55%
02:00pm Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
12:54pm Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT

Evolution of the average Target Price on Bristol-Myers Squibb Company

Price target over the last 5 years

History of analyst recommendation changes

d4f19f49f0e5.i0ZhDzJpi0u4glyZY2hvi1K6134dwv8FnkAs10JzZbo.vxEURwUmyQSO-HHLNgkW_wjcpRYtrrJv2zJJlG8pHdOmIQZMBwr6ZvvyDQ~10d35372b9424f1f5deb6c09db618c10

Analyst Recommendations on Bristol-Myers Squibb Company

Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51 MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65 MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40 MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55 MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85 MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77 MT
That's good enough for investors Our Logo
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla... Our Logo
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $41 From $42, Incorporates Mirati Transaction Into Model; Underweight Kept MT
UBS Cuts Bristol-Myers Squibb Price Target to $52 From $57, Maintains Neutral Rating MT
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
44.85 USD
Average target price
54.02 USD
Spread / Average Target
+20.45%
High Price Target
75 USD
Spread / Highest target
+67.22%
Low Price Target
37 USD
Spread / Lowest Target
-17.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bristol-Myers Squibb Company

Leerink Partners
UBS
Barclays
JPMorgan Chase
Morgan Stanley
Truist Securities
BMO Capital
Jefferies & Co.
Cantor Fitzgerald
Wells Fargo Securities
Wolfe Research
Societe Generale
Redburn
BofA Securities
Deutsche Bank Securities
Daiwa Securities
Berenberg Bank
Goldman Sachs
William Blair & Co.
HSBC
TD Cowen
Credit Suisse
Atlantic Equities
Guggenheim
Raymond James
Citigroup
Argus

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Consensus Bristol-Myers Squibb Company